201 Elliott Avenue West
About Omeros Corporation
At Omeros, we are proud of our innovative and cutting-edge science. Our world-class team has achieved scientific advances that no other group has been able to accomplish, delivering wholly new classes of therapeutics to benefit patients. We let science lead the way.
From our foundation of groundbreaking science, we continue to build and advance a deep and diverse pipeline of small-molecule and protein therapeutics. We are not interested in developing “me-too” products; instead, we are focused on tackling challenging diseases and disorders with significant unmet medical needs. The result is an exciting pipeline of first-in-class drugs with new mechanisms of action that target previously untapped receptors and enzymes.
The Omeros team is exceptionally talented, passionate, collaborative and diverse. We hire smart, creative and hard-working people who want to play a meaningful part in building a preeminent biopharmaceutical company. We come from all corners of the globe, bringing unique abilities and experiences together to provide hope to patients and their families.
389 articles with Omeros Corporation
Omeros Corporation announced that it has commenced a registered underwritten public offering of its common stock.
Omeros Reports Positive Data Across Primary and Secondary Endpoints in Pivotal Trial of Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy Patients Treated with Narsoplimab
Omeros Corporation (Nasdaq: OMER) today announced positive data from its pivotal clinical trial of the company’s novel investigational complement inhibitor narsoplimab in the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA), a frequently lethal complication of HSCT.
Omeros’ New GPR174 Immuno-oncology Data Presented at the American Association for Cancer Research Conference In Boston Now Available Online
The positively received and well-attended presentation about the company’s cell-based and animal studies related to its newly discovered cancer immunity axis was made by Marc Gavin, Ph.D., Omeros’ Director of Immunology.
Omeros Presents New GPR174 Immuno-oncology Data Today at the American Association for Cancer Research Conference in Boston
Omeros Corporation (Nasdaq: OMER) today announced new findings on GPR174, its novel cancer immunotherapy target, demonstrating that GPR174-deficiency enhances anti-tumor immune responses in animals.
Omeros Corporation announced recent highlights and developments as well as financial results for the third quarter ended September 30, 2019.
Omeros to Present GPR174 Data at Upcoming American Association for Cancer Research Conference on Tumor Immunology and Immunotherapy
Omeros Corporation (Nasdaq: OMER) today announced an upcoming presentation entitled “Phosphatidylserine suppresses T cells through GPR174, and co-inhibition of adenosine receptors and GPR174 synergistically enhances T-cell responses” at the American Association for Cancer Research Conference on Tumor Immunology and Immunotherapy, which is being held November 17 - 20, 2019 in Boston, Massachusetts.
Prestigious Prize Conferred for GPCR Program Discoveries
Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its third quarter 2019 financial results for the period ended September 30, 2019, on Tuesday, November 12, 2019, after the market closes.
Omeros Corporation Announces Publication of Study Results on the Impact of OMIDRIA on Opioid Use and Pain
Study Demonstrates Opioid-Sparing Requirement of OMIDRIA for CMS Packaging Exclusion
Omeros’ Narsoplimab Receives Positive Opinion from European Medicines Agency for Pediatric Investigation Plan Required for MAA Submission
Includes Deferral for PIP Completion Until After Approval of Marketing Authorization Application
Rolling Submission of the Remaining BLA Sections Continues On Track for Scheduled Completion 1H 2020
Omeros Corporation announced that the product-specific J-code for OMIDRIA® 1% / 0.3% is now effective.
Omeros Announces Publication of Study Showing that Inhibition of MASP-2, the Key Enzyme of the Complement System’s Lectin Pathway, Protects Against Renal Injury Caused by Proteinuria
The article is published in Frontiers in Immunology and entitled “Absence of the Lectin Activation Pathway of Complement Ameliorates Proteinuria-Induced Renal Injury,”
Omeros Corporation Announces Positive Results from Phase 1 Study of its Lead PDE7 Inhibitor in Development for Addiction
Phase 1 study results show excellent safety and PK profile consistent with once-daily dosing
The Company’s GPR174 Inhibitors Enhance Anti-Tumor Activities of Adenosine Pathway Inhibitors by up to 25-Fold
Omeros Corporation announced that Gregory A. Demopulos, M.D., chairman and chief executive officer, will present at the H.C. Wainwright 21st Annual Global Investment Conference in New York next week.
Omeros Corporation (Nasdaq: OMER), today announced that Gregory A. Demopulos, M.D., chairman and chief executive officer, will present at the 2019 Wedbush PacGrow Healthcare Conference in New York next week.
Omeros Corporation announced recent highlights and developments as well as financial results for the second quarter ended June 30, 2019.
Omeros Corporation announced that the company will issue its second quarter 2019 financial results for the period ended June 30, 2019, on Thursday, August 8, 2019, after the market closes.
Omeros and Lonza have successfully partnered under a multi-year manufacturing agreement for the clinical supply of narsoplimab.